Vytrus Biotech S.A. (VYT) - Cash Flow Conversion Efficiency

Latest as of December 2022: 0.047x

Based on the latest financial reports, Vytrus Biotech S.A. (VYT) has a cash flow conversion efficiency ratio of 0.047x as of December 2022. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€225.55K ≈ $263.69K USD) by net assets (€4.75 Million ≈ $5.56 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See VYT equity financing ratio to measure how much of total assets are equity-financed.

Vytrus Biotech S.A. - Cash Flow Conversion Efficiency Trend (2020–2025)

This chart illustrates how Vytrus Biotech S.A.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Vytrus Biotech S.A. cash flow quality index to evaluate the quality of earnings relative to operating cash generation.

Vytrus Biotech S.A. Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Vytrus Biotech S.A. ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Nynomic AG
F:M7U
-0.045x
YESASIA HOLDINGS LTD
F:4CM
N/A
CVC Ltd
AU:CVC
-0.098x
Borosil Scientific
NSE:BOROSCI
N/A
Wintermar Offshore Marine Tbk
JK:WINS
0.069x
Hanla IMS Co. Ltd
KQ:092460
0.030x
Wah Seong Corporation Bhd
KLSE:5142
0.056x
GrafTech International Ltd
NYSE:EAF
0.080x

Annual Cash Flow Conversion Efficiency for Vytrus Biotech S.A. (2020–2025)

The table below shows the annual cash flow conversion efficiency of Vytrus Biotech S.A. from 2020 to 2025. For the full company profile with market capitalisation and key ratios, see VYT market cap.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-12-31 €10.31 Million
≈ $12.05 Million
€3.90 Million
≈ $4.56 Million
0.378x +49.65%
2024-12-31 €7.29 Million
≈ $8.53 Million
€1.84 Million
≈ $2.16 Million
0.253x +47.95%
2023-12-31 €5.29 Million
≈ $6.19 Million
€904.39K
≈ $1.06 Million
0.171x +260.14%
2022-12-31 €4.75 Million
≈ $5.56 Million
€225.55K
≈ $263.69K
0.047x -54.97%
2021-12-31 €4.25 Million
≈ $4.97 Million
€447.92K
≈ $523.67K
0.105x +387.17%
2020-12-31 €3.61 Million
≈ $4.22 Million
€-132.47K
≈ $-154.87K
-0.037x --

About Vytrus Biotech S.A.

MC:VYT Spain Biotechnology
Market Cap
$151.15 Million
€129.28 Million EUR
Market Cap Rank
#18054 Global
#117 in Spain
Share Price
€17.20
Change (1 day)
+2.08%
52-Week Range
€5.45 - €19.80
All Time High
€19.80
About

Vytrus Biotech, S.A. develops, produces, and sells active ingredients from plant stem cells in Spain and internationally. It offers Clarivine that activates skin's regeneration processes; Quora Noni biomics for rejuvenating the skin microbiota; Deobiome Noni, a prebiotic deodorant to reduce the generation of body odour; Sarcoslim Re-Shape, an active ingredient to reduce fat on tissue; Capilia Lon… Read more